Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Abstract

Treatment with agalsidase beta at higher dose compared with agalsidase alfa does not result in a difference in clinical events, which occurred especially in those with more advanced disease. A greater biochemical response, also in the presence of antibodies, and better reduction in left ventricular mass was observed with agalsidase beta.